Skip to main content

Table 2 Baseline laboratory characteristics of patients with COVID-19

From: Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Variables

Total (n = 91)

Severe (30, 33.0%)

Mild (61, 67.0%)

P value

WBC (×10^9/L)

0.127

 <4

27/91 (29.7%)

7/30 (23.3%)

20/61 (32.8%)

 

 4–10

53/91 (58.2%)

18/30 (60.0%)

35/61 (57.4%)

 

 >10

11/91 (12.1%)

5/30 (16.7%)

6/61 (9.8%)

 

Neutrophil (×10^9/L)

0.467

  ≤ 6.3

80/91 (87.9%)

26/30 (86.7%)

54/61 (88.5%)

 

 >6.3

11/91 (12.1%)

4/30 (13.3%)

7/61 (11.5%)

 

Monocytes (×10^9/L)

0.190

  ≤ 0.6

66/91 (72.5%)

20/30 (66.7%)

46/61 (75.4%)

 

 >0.6

25/91 (27.5%)

10/30 (33.3%)

15/61 (24.6%)

 

Lymphocytes (×10^9/L)

0.022

  ≤ 1.1

47/91 (51.6%)

11/30 (36.7%)

36/61 (59.0%)

 

 >1.1

44/91 (48.4%)

19/30 (63.3%)

25/61 (41.0%)

 

CTnI (μg/L)

0.277

  ≤ 0.01

85/88 (96.6%)

28/30 (93.3%)

57/58 (98.3%)

 

 >0.01

3/88 (3.4%)

2/30 (6.7%)

1/58 (1.7%)

 

CK (U/L)

0.018

  ≤ 190

77/91 (84.6%)

22/30 (73.3%)

55/61 (90.0%)

 

 >190

14/91 (15.4%)

8/30 (26.7%)

6/61 (9.8%)

 

CK-MB (U/L)

0.099

  ≤ 24

87/91 (95.6%)

27/30 (90.0%)

60/61 (98.4%)

 

 >24

4/91 (4.4%)

3/30 (10.0%)

1/61 (1.6%)

 

ALT (U/L)

0.112

  ≤ 50

81/91 (89.0%)

25/30 (83.3%)

56/61 (91.8%)

 

 >50

10/91 (11.0%)

5/30 (16.7%)

5/61 (8.2%)

 

AST (U/L)

0.124

  ≤ 40

73/91 (80.0%)

22/30 (73.3%)

51/61 (83.6%)

 

 >40

18/91 (19.8%)

8/30 (26.7%)

10/61 (16.4%)

 

Cr (μmol/L)

0.000

  ≤ 97

86/91 (94.5%)

25/30 (83.3%)

61/61 (100%)

 

 >97

5/91 (5.5%)

5/30 (16.7%)

0/61 (0%)

 

UA (μmol/L)

0.202

  ≤ 417

86/91 (94.5%)

27/30 (90.0%)

59/61 (96.7%)

 

 >417

5/91 (5.5%)

3/30 (10.0%)

2/61 (3.3%)

 

PT (s)

0.100

  ≤ 12.8

72/91 (79.1%)

22/30 (73.3%)

50/61 (82%)

 

 >12.8

19/91 (20.9%)

8/30 (26.7%)

11/61 (18.0%)

 

APTT(s)

0.202

  ≤ 36.5 s

86/91 (94.5%)

27/30 (90.0%)

59/61 (96.7%)

 

 >36.5

5/91 (5.5%)

3/30 (10.0%)

2/61 (3.3%)

 

D-Dimer (ng/ml)

0.484

  ≤ 232

78/82 (95.1%)

28/30 (93.3%)

50/52 (96.2%)

 

 >232

4/82 (4.9%)

2/30 (6.7%)

2/52 (3.8%)

 

IL-6 (ng/ml)

0.485

  ≤ 7

73/91 (80.2%)

24/30 (80.0%)

49/61 (80.3%)

 

 >7

18/91 (19.8%)

6/30 (20.0%)

12/61 (19.7%)

 

CRP (mg/ml)

0.240

  ≤ 10

56/91 (61.5%)

20/30 (66.7%)

36/61 (59.0%)

 

 >10

35/91 (38.5%)

10/30 (33.3%)

25/61 (41.0%)

 

PCT (ng/ml)

0.106

  ≤ 0.5

85/89 (95.5%)

27/30 (90.0%)

58/59 (98.3%)

 

 >0.5

4/89 (4.5%)

3/30 (10.0%)

1/59 (1.7%)

 
  1. Data are n/N (%), where N is the total number of patients with available data. p values comparing severe and mild groups used Chi-square test, Chi-square with Yates’ correction, or Fisher’s exact test
  2. WBC White blood cell, CTnI Cardiac troponin I, CK Creatine kinase, CK-MB Creatine kinase isoenzyme, ALT Alanine aminotransferase, AST Aspartate aminotransferase, Cr Creatinine, UA Uric acid, PT Prothrombin time, APTT Activated partial thromboplastin time, IL-6 Interleukin 6, CRP C-reactive protein, PCT Procalcitonin